261780.Kq
The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.
Business. The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, primarily generating revenue through pharmaceutical and medical research activities.
The company's capital structure is characterized by a high debt-to-equity ratio of 0.75, indicating a moderate reliance on debt financing. The liquidity position is assessed as medium, with a current ratio of 1.66, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's negative operating and free cash flows, at -11,017.07 million KRW and -15,744.78 million KRW respectively, indicate a lack of cash generation from operations.
Profitability metrics are weak, with a return on equity (ROE) of -1.35 and a return on assets (ROA) of -0.54, both significantly below the industry median. The company's net loss of -16,044.49 million KRW and operating loss of -14,472.08 million KRW further underscore its unprofitable operations. Gross profit of 14,391.82 million KRW is the only positive earnings metric, but it is insufficient to offset the company's operational costs.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases the company's exposure to market-specific risks and limits its ability to offset losses in one area with gains in another.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The company's operating cash flow and free cash flow are both negative, indicating a lack of internal cash generation to fund future growth. The company's capital expenditures of -155.92 million KRW suggest a minimal investment in long-term assets, which may limit its ability to scale operations or develop new products.
The company's risk profile is elevated, with a medium liquidity risk and a low dilution risk. The company's negative net cash position, after subtracting total debt, is a key flag indicating potential liquidity constraints. The company's dilution risk is low, with no significant dilution potential reported in the available data. However, the company's high debt levels and negative cash flows may necessitate future financing, which could lead to dilution if equity is used to raise capital.
Recent events, as disclosed in the company's financial filings, include a significant operating and net loss, which may impact investor confidence. The company has not disclosed any recent strategic initiatives or product launches that could drive future revenue growth. The absence of recent positive developments may contribute to a bearish outlook for the company's stock.
- The company is operating at a significant net and operating loss, with negative cash flows from operations.
- The company's capital structure is moderately leveraged, with a debt-to-equity ratio of 0.75.
- The company's profitability metrics are weak, with a negative return on equity and return on assets.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company's liquidity position is medium, with a current ratio of 1.66, but it has negative operating and free cash flows.
- The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 261780.KQ Market data — financials · 2026-05-26